{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5ef0acf44320b108b12f7e8b/6a5903b8f782764c4cfd4f98?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"Symposium | Future perspectives for cytopenic MF: Panel discussion and Q&A ","description":"<p>At the European School of Haematology (ESH) 11th Translational Research Conference: Myeloproliferative Neoplasms, Apr 24–26, 2026, Estoril, PT, the MPN Hub held a symposium, titled Patient-centered approaches in myelofibrosis: Tailoring treatment for anemia and thrombocytopenia. During the symposium, MPN Hub Steering Committee Chair Jean-Jacques Kiladjian, Université Paris Cité - Hôpital Saint-Louis, Paris, FR, and Steering Committee members Steffen Koschmieder, Uniklinik RWTH Aachen, DE, and Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, discussed future perspectives for cytopenic myelofibrosis (MF) during a panel discussion and Q&amp;A session.&nbsp;</p><p><br></p><p>In this presentation, Kiladjian, Koschmieder, and Harrison discuss practical approaches to the management of cytopenias in myelofibrosis, including treatment selection, management of treatment-emergent anemia, supportive care strategies, and future directions for individualized and combination therapies.&nbsp;</p><p><br></p><p><em>This educational resource is independently supported by GSK. All content is developed by the faculty in collaboration with SES. Funders are allowed no influence.&nbsp;</em></p>","author_name":"Scientific Education Support"}